SLGL Earnings Date: Nov 19, 2026 (Estimated) — Sol-Gel Technologies Ltd.
NASDAQ · Healthcare · Biotechnology
Updated
When is SLGL's next earnings date?
Sol-Gel Technologies Ltd. (SLGL) is expected to report Q3 2026 earnings on Thursday, November 19, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$2.07 on revenue of $150,000.
How did SLGL do in its last earnings report?
In its most recent report on Aug 20, 2026 (Q2 2026), Sol-Gel Technologies Ltd. posted EPS of -$1.13 versus the -$2.36 estimate, a beat of 51.1%. Revenue was $591,000 against a $75,000 estimate. The stock's 1-day post-earnings move was -0.1%.
How much does SLGL stock move after earnings?
SLGL beat EPS estimates in 4 of its last 7 reported quarters. Over the last 8 reports the stock moved an average of 3.0% (up or down) in the day after earnings.
About Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd., a pharmaceutical firm currently in its clinical development phase, specializes in the creation and market introduction of skin-applied medications. These products leverage the company's distinctive microencapsulation technology, with their primary development and commercialization activities centered in Israel. Sol-Gel's pipeline features several key candidates. Twyneo, an innovative, non-antibiotic topical cream designed for once-daily application, has successfully concluded Phase III trials for treating acne vulgaris. Similarly, Epsolay, another topical cream administered once a day, has also completed its Phase III studies, targeting papulopustular rosacea. Advancing through Phase I clinical trials is SGT-210, intended for palmoplantar keratoderma. Furthermore, the company is investigating Erlotinib, Tapinarof, and Roflumilast as potential treatments for psoriasis and various other medical conditions. Beyond its proprietary offerings, the company also engages in creating generic versions of topical dermatological medications. Sol-Gel Technologies maintains a strategic partnership with Perrigo. Established in 1997, the company maintains its headquarters in Ness Ziona, Israel.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-20 | Q2 2026 | -2.36 | -1.13 | +51.08% | $591,000 | ✅ Beat | -0.12% | +1.07% | -23.65% |
| 2026-05-28 | Q1 2026 | -2.66 | -1.31 | +50.75% | $108,000 | ✅ Beat | +2.01% | -3.12% | -0.41% |
| 2026-03-19 | Q4 2025 | 0.39 | -1.06 | -371.79% | $696,000 | ❌ Miss | +8.46% | +4.95% | -1.95% |
| 2025-11-20 | Q3 2025 | -2.09 | -2.13 | -1.91% | $400,000 | ❌ Miss | -0.80% | +12.90% | +16.98% |
| 2025-08-15 | Q2 2025 | — | 4.17 | — | $17.3M | — | +1.25% | +69.18% | +57.25% |
| 2024-11-15 | Q3 2024 | -0.13 | -0.01 | +92.31% | $5.4M | ✅ Beat | +3.00% | -4.98% | -6.82% |
| 2024-08-16 | Q2 2024 | -0.20 | 0.07 | +135.00% | $5.4M | ✅ Beat | +2.57% | +65.45% | +52.38% |
| 2024-05-20 | Q1 2024 | -0.15 | -0.23 | -53.33% | $466,000 | ❌ Miss | -6.00% | +6.67% | +15.96% |
Showing last 8 quarters.
Revenue by segment & region
By region
FY2025 · $19.4M total · annual
| Segment | Share | Revenue | YoY | FY2025 |
|---|---|---|---|---|
| UNITED STATES | 86.1% | $16.7M | — | $16.7M |
| CANADA | 8.6% | $1.7M | +146.3% | $1.7M |
| SWITZERLAND | 3.7% | $711K | -52.0% | $711K |
| Segment Geographical Groups Of Countries Group Five | 1.4% | $278K | -59.8% | $278K |
| CHINA | 0.1% | $27K | -99.4% | $27K |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.